Middle East Journal of Cancer

Comparison of Interleukin-18 Serum Levels in Patients with Breast Cancer and Idiopathic Granulomatous Mastitis

Document Type : Original Article(s)

Authors

Marzieh Haghbin 1
Akbar Hashemi Tayer 1
Farnaz Abbasi 2
Mohammad Reza Haghshenas 3
Abdolreza Sotoodeh Jahromi 1

1 Research Center for Noncommunicable Diseases , Jahrom University of Medical Sciences, Jahrom, Iran

2 Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran

3 Shiraz Institue for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

https://doi.org/10.30476/mejc.2024.102976.2119
Abstract
Background: Breast cancer (BC), as a global challenge, is one of the most prevalent malignant diseases among women. Idiopathic granulomatous mastitis (IGM) is a rare, chronic inflammatory breast disease that primarily affects women of fertility age. IGM mimics symptoms and radiographic patterns of BC. IL-18 plays a dual role in cancer, as it can promote tumor growth or reduce tumor growth. Therefore, this study aimed to compare the serum levels of IL-18 in BC and IGM patients.
Method: This case-control study was conducted on 45 patients with BC, 25 with IGM (I), and 30 healthy individuals (C) with normal screening tests as the control group. The BC group consisted of 25 newly diagnosed BC patients (N), and 20 patients with metastatic BC (M). Specialized pathologists confirmed the histopathological pattern of BC and IGM. Enzyme-linked immunosorbent assay (ELISA) sandwich technique was used for the measurement of IL-18 serum levels. All statistical analyses were performed using SPSS-23, and GraphPad Prism. P <0.05 was considered statistically significant.
Results: The serum level of IL-18 showed statistically significant higher values in the three patient groups than the control group (P < 0.001). In addition, the IL-18 levels in the M group were significantly higher than in the N and I groups (P < 0.01). There was no statistical significance between N and I groups (P > 0.05).
Conclusion: IL-18 levels were significantly elevated in BC compared with the IGM and control groups. IL-18 has a potential role as a prognostic indicator in BC, particularly for patients with metastasis.

Highlights

Marzieh Haghbin (PubMed)

Akbar Hashemi Tayer (Google Scholar)

Keywords

Breast neoplasms
Granulomatous mastitis
Interleukin-18
Metastasis
Subjects

How to cite this article:

Haghbin M, Hashemi Tayer A, Abbasi F, Haghshenas MR, Sotoodeh Jahromi A. Comparison of Interleukin-18 Serum Levels in Patients with Breast Cancer and Idiopathic Granulomatous Mastitis. Middle East J Cancer. 2025;16(3):279-87. doi: 10.30476/mejc.2024. 102976.2119.

 

  1. Robertson S, Azizpour H, Smith K, Hartman J. Digital image analysis in breast pathology-from image processing techniques to artificial intelligence. Transl Res. 2018;194:19-35. doi: 10.1016/j.trsl.2017.10.010. PMID: 29175265.
  2. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1):33. doi: 10.1186/s40659-017-0140-9. PMID: 28969709; PMCID: PMC5625777.
  3. Waks AG, Winer EP. Breast cancer treatment: A review. JAMA. 2019;321(3):288-300. doi: 10.1001/jama.2018.19323. PMID: 30667505.
  4. Sadoughi F, Kazemy Z, Hamedan F, Owji L, Rahmanikatigari M, Azadboni TT. Artificial intelligence methods for the diagnosis of breast cancer by image processing: a review. Breast Cancer (Dove Med Press). 2018;10:219-30. doi: 10.2147/BCTT.S175311. PMID: 30555254; PMCID: PMC6278839.
  5. Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer. 2018;92:54-68. doi: 10.1016/j.ejca.2017.12.025. PMID: 29413690.
  6. Wang J, Zhang Y, Lu X, Xi C, Yu K, Gao R, Bi K. Idiopathic granulomatous mastitis with skin rupture: A retrospective cohort study of 200 patients who underwent surgical and nonsurgical treatment. J Invest Surg. 2021;34(7):810-15. doi:10.1080/08941939.2019.1696905. PMID: 31818161.
  7. Manogna P, Dev B, Joseph LD, Ramakrishnan R.Idiopathic granulomatous mastitis—our experience. Egypt J Radiol Nucl Med. 2020; 51(1):15. doi.10.1186/s43055-019-0126-4
  8. Chirappapha P, Thaweepworadej P, Supsamutchai C, Biadul N, Lertsithichai P. Idiopathic granulomatous mastitis: A retrospective cohort study between 44 patients with different treatment modalities. Ann Med Surg (Lond). 2018;36:162-67. doi: 10.1016/j.amsu.2018.11.001. PMID: 30479764; PMCID: PMC6240599.
  9. Yin Y, Liu X, Meng Q, Han X, Zhang H, Lv Y. Idiopathic granulomatous mastitis: etiology, clinical manifestation, diagnosis and treatment. J Invest Surg. 2022;35(3):709-20. doi: 10.1080/08941939.2021.1894516. PMID: 33691563.
  10. Haghbin M, Sotoodeh Jahromi A, Ranjbaran R, Abbasi M, Hashemi Tayer A. Comparison of interleukin-33 serum levels in patients with breast cancer and idiopathic granulomatous mastitis. Asian Pac J Cancer Prev. 2023;24(5):1629-34. doi: 10.31557/APJCP.2023.24.5.1629. PMID: 37247282; PMCID: PMC10495896.
  11. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-26. doi: 10.4103/aam.aam_56_18. PMID: 31417011; PMCID: PMC6704802.
  12. Wu B, Sodji QH, Oyelere AK. Inflammation, fibrosis and cancer: Mechanisms, therapeutic options and challenges. Cancers (Basel). 2022;14(3):552. doi: 10.3390/cancers14030552. PMID: 35158821; PMCID: PMC8833582.
  13. Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci. 2019;20(3):649. doi: 10.3390/ijms20030649. PMID: 30717382; PMCID: PMC6387150.
  14. Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2015;97(4):665-75. doi: 10.1189/jlb.5RU0714-360RR. PMID: 25548255.
  15. Ihim SA, Abubakar SD, Zian Z, Sasaki T, Saffarioun M, Maleknia S, et al. Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment. Front Immunol. 2022;13:919973. doi: 10.3389/fimmu.2022.919973. PMID: 36032110; PMCID: PMC9410767.
  16. Inoue N, Li W, Fujimoto Y, Matsushita Y, Katagiri T, Okamura H, et al. High serum levels of Interleukin-18 are associated with worse outcomes in patients with breast cancer. Anticancer Res. 2019;39(9):5009-18. doi: 10.21873/anticanres.13691. PMID: 31519608.
  17. Yang Y, Cheon S, Jung MK, Song SB, Kim D, Kim HJ, et al. Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway. Biochem Biophys Res Commun. 2015;459(3):379-86. doi: 10.1016/j.bbrc.2015.02.108. PMID: 25727011.
  18. Harvey RE, Coffman KE, Miller VM. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. Womens Health (Lond). 2015;11(2):239-57. doi: 10.2217/whe.14.64. PMID: 25776297; PMCID: PMC4386625.
  19. Lindegaard B, Abildgaard J, Heywood SE, Pedersen BK, Febbraio MA. Female sex hormones are necessary for the metabolic effects mediated by loss of interleukin 18 signaling. Mol Metab. 2018;12:89-97. doi: 10.1016/j.molmet.2018.04.005. PMID: 29699928; PMCID: PMC6001917.
  20. Averyanova M, Yureneva S, Kiseleva V, Yakushevskaya O, Iskusnykh M, Pavlova A, et al. Effect of menopausal hormone therapy on cellular immunity parameters and cytokine profile. Biomedicines. 2024; 12(8):1892. doi:10.3390/biomedicines12081892.
  21. Schafer M, Schiller D. Navigating social space. Neuron. 2018;100(2):476-89. doi: 10.1016/j.neuron.2018.10.006. PMID: 30359610; PMCID: PMC6226014.
  22. Ma T, Kong M. Interleukin-18 and -10 may be associated with lymph node metastasis in breast cancer. Oncol Lett. 2021;21(4):253. doi: 10.3892/ol.2021.12515. PMID: 33664817; PMCID: PMC7882877.
  23. El-Deeb MMK, El-Sheredy HG, Mohammed AF. The possible role of interleukin (IL)-18 and nitrous oxide and their relation to oxidative stress in the development and progression of breast cancer. Asian Pac J Cancer Prev. 2019;20(9):2659-65. doi: 10.31557/APJCP.2019.20.9.2659. PMID: 31554361; PMCID: PMC6976825.
  24. Aref S, El-Ghonemy MS, El-Aziz SA, Abouzeid T, Talaab M, El-Sabbagh A. Impact of serum immunoglobulins level and IL-18 promoter gene polymorphism among Egyptian patients with idiopathic thrombocytopenic purpura. Hematology. 2017;22(2):99-104. doi: 10.1080/10245332.2016.1221213. PMID: 27600402.
  25. Janho Dit Hreich S, Hofman P, Vouret-Craviari V. The role of IL-18 in P2RX7-mediated antitumor immunity. Int J Mol Sci. 2023;24(11):9235. doi: 10.3390/ijms24119235. PMID: 37298187; PMCID: PMC10252498.
  26. Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in breast cancer progression, diagnosis, and treatment. J Cancer. 2020;11(15):4474-94. doi: 10.7150/jca.44313. PMID: 32489466; PMCID: PMC7255381.
  27. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263. doi: 10.1038/s41392-021-00658-5. PMID: 34248142; PMCID: PMC8273155.
  28. Aguiar MAN, Wanderley CWS, Nobre LMS, Alencar MRM, Saldanha MDPS, Souza AM, et al. Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: A possible association with chemotherapy response. Asia Pac J Clin Oncol. 2018;14(2):e138-e144. doi: 10.1111/ajco.12722. PMID: 28766916.
  29. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559-72. doi: 10.1038/nri.2017.49. PMID: 28555670; PMCID: PMC5731833.
  30. Maharjan CK, Mo J, Wang L, Kim MC, Wang S, Borcherding N, et al. Natural and synthetic estrogens in chronic inflammation and breast cancer. Cancers (Basel). 2021;14(1):206. doi: 10.3390/cancers14010206. PMID: 35008370; PMCID: PMC8744660.
  31. Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far. Genes Dis. 2016;3(2):114-23. doi: 10.1016/j.gendis.2016.02.002. PMID: 30123819; PMCID: PMC6095671.
Middle East Journal of Cancer
Volume 16, Issue 3
Summer 2025
Pages 279-287

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us